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Aims: Cytokines interfere with signaling pathways and mediators of vascular contraction. Endothelin-1 (ET-1)
plays a major role on vascular dysfunction in conditions characterized by increased circulating levels of
adipokines. In the present study we tested the hypothesis that the adipokine chemerin increases vascular con-
tractile responses via activation of ET-1/ET-1 receptors-mediated pathways.
Main methods: Male, 10–12 week-old Wistar rats were used. Endothelium-intact and endothelium-denuded
aortic rings were incubated with chemerin (0.5 ng/mL or 5 ng/mL, for 1 or 24 h), and isometric contraction
was recorded. Protein expression was determined by Western blotting.
Key ﬁndings: Constrictor responses to phenylephrine (PE) and ET-1 were increased in vessels treated for 1 h
with chemerin. Chemerin incubation for 24 h decreased PE contractile response whereas it increased the sensi-
tivity to ET-1. Endothelium removal signiﬁcantly potentiated chemerin effects on vascular contractile responses
to PE and ET-1. Incubation with either an ERK1/2 inhibitor (PD98059) or ETA antagonist (BQ123) abolished
chemerin effects on PE- and ET-1-induced vasoconstriction. Phosphorylation of MEK1/2 and ERK1/2 was signif-
icantly increased in vessels treated with chemerin for 1 and 24 h. Phosphorylation of these proteins was further
increased in vessels incubated with ET-1 plus chemerin. ET-1 increased MEK1/2, ERK1/2 and MKP1 protein
expression to values observed in vessels treated with chemerin.
Signiﬁcance: Chemerin increases contractile responses to PE and ET-1 via ERK1/2 activation. Our study contributes
to a better understanding of themechanisms bywhich the adipose tissue affects vascular function and, consequent-
ly, the vascular alterations present in obesity and related diseases.© 2012 Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
The white adipose tissue has been recognized as an endocrine
organ that releases anti-inﬂammatory adipokines, like adiponectin, and
pro-inﬂammatory adipokines, like tumor necrosis factor-alpha (TNF-α),
interleukin-6 (IL-6), monocyte chemoattractant protein-1 (MCP-1), and
plasminogen activator inhibitor-1 (Ahima, 2006; Galic et al., 2010;
Guerre-Millo, 2004; Trayhurn and Wood, 2005). The balance between
the actions of these adipokines is affected in many cardiovascular
diseases and seems to be implicated in the alterations of vascular function
associated with these conditions (Weisberg et al., 2003; Xu et al., 2003;
Matsuzawa, 2005).
Vascular reactivity to contractile/relaxant stimuli is one of the most
important determinants of vascular tonus. Previous studies have shownSciences, Federal University of
ato).
-NC-ND license.that adipokines can potentially affect vascular reactivity (Klemm et al.,
1995; Vicaut et al., 1996; Pickkers et al., 2002; Vila and Mercedes,
2005). Therefore, it is highly likely that adipokines might contribute to
the genesis of vascular dysfunction by directly affecting vascular reac-
tivity. In addition to the classical adipokines, a novel adipokine, termed
chemerin, was recently discovered (Wittamer et al., 2003; Bozaoglu et
al., 2007; Goralski et al., 2007; Roh et al., 2007). Chemerinwas originally
identiﬁed as a chemoattractant for immune cells such as macrophages
and dendritic cells (Wittamer et al., 2004). However, chemerin receptor
is also expressed in endothelial cells, and its expression is regulated by
inﬂammatory cytokines, including TNF-α, IL-1β, and IL-6 (Kaur et al.,
2010). Thus, it is likely that chemerin contributes to changes in vascular
reactivity in inﬂammatory states. Accordingly, increased chemerin
expression was demonstrated in adipocytes from mice fed a high fat
diet (Roh et al., 2007). In addition, serum and adipose tissue chemerin
levels are increased in women with metabolic syndrome (Bozaoglu
et al., 2009). In humans, blood chemerin concentration seems to be
associated with components of metabolic syndrome, such as body
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is frequently present in conditions associated with altered vascular
function, no studies have speciﬁcally assessed its vascular effects.
The endothelin-1 (ET-1) system contributes to vascular dysfunction
in cardiovascular diseases, and, accordingly, circulating levels of ET-1
are increased in a variety of vascular diseases (Schiffrin, 2005; Carneiro
et al., 2008; Weil et al., 2011). The effect of pro-inﬂammatory cytokines
on ET-1 system is of great relevance, because in many situations where
the levels of pro-inﬂammatory cytokines are elevated, the activity of
ET-1 is also altered (Pasceri et al., 2000; Cooke and Oka, 2002; Verma et
al., 2003; Molet et al., 2000). Increased levels of ET-1 are associated
with augmented activation of MAPKs, especially ERK 1/2, a major signal-
ing pathway activated by ET-1 in the vascular system (Kobayashi et al.,
2008; Matsumoto et al., 2009).
Based on these observations, we hypothesized that chemerin
augments vascular responses to contractile stimuli via activation of
ET-1/ET-1 receptor-mediated pathways. To test our hypothesis, the
effects of chemerinwere determined in isolated aortic rings. The contri-
bution of ET-1 to chemerin effects was assessed by pharmacological
inhibition of the MEK-ERK1/2 pathway and ETA receptors as well as
by molecular approaches.
Methods
Animals
All experimental protocols were performed in accordance with
the Guide for the Care and Use of Laboratory Animals published by
the US National Institutes of Health (NIH Publication No. 85–23,
revised 1996). Protocols were approved by the Committee for Animal
Research of the University of Sao Paulo, Ribeirao Preto, Brazil (Proto-
col No. 10.1.1295.53.7/11) and by the Medical College of Georgia
Committee on the Use of Animals in Research and Education. Ten
to twelve week-old male Wistar rats (purchased from Harlan Labora-
tories, Indianapolis, IN) were used. The rats were maintained on a
12-hour light/dark cycle under controlled temperature (22±1 °C)
with access to food and water ad libitum.
Chemerin incubation procedures
After euthanasia, thoracic aortas were rapidly excised and cleaned
from fat tissue in an ice-cold (4 °C) Krebs–Henseleit-modiﬁed so-
lution [(in mM): 130 NaCl, 14.9 NaHCO3, 4.7 KCl, 1.18 KH2PO4, 1.17
MgSO4⋅7H2O, 5.5 glucose, 1.56 CaCl2⋅2H2O, and 0.026 EDTA], gassed
with 5% CO2/95% O2 to maintain a pH of 7.4. Aortic rings (2–3 mm in
length)weremounted on 2 stainless-steelwires in standard organ cham-
bers for isometric tension recording, as described previously (Giachini et
al., 2008). Vessels were allowed to equilibrate for about 30 min in
Krebs–Henseleit solution. After the stabilization period, arterial integrity
was assessed ﬁrst by stimulation of vessels with 120 mmol/L of KCl.
After washing and a new stabilization period, endothelial function was
assessed by testing the relaxant effect of acetylcholine (ACh, 1 μM) on
vessels contracted with phenylephrine (PE, 1 μM). Aortic rings exhibiting
a vasodilator response to ACh greater than 90% were considered
endothelium-intact vessels. In experiments with endothelium-denuded
vessels, aortic rings were subjected to rubbing of the intimal surface.
Rings showing amaximumof 5% relaxation toAChwere consideredwith-
out endothelium.
Arterial segments were incubated with either vehicle (phosphate
buffer solution, PBS) or chemerin (0.5 ng/mL and 5 ng/mL) for 1 h
to verify acute effects of the cytokine. In another set of experiments,
aortas were functionally evaluated after incubations for 24 h with ve-
hicle (PBS) or chemerin (0.5 ng/mL and 5 ng/mL) in Eagle minimum
essential medium containing l-glutamine (1.0%), fetal bovine serum
(FBS, 10.0%), penicillin (0.5%), and streptomycin (0.5%). Pilot studies
were performed before these concentrations of chemerin wereselected. Chemerin was tested at the concentrations: 0.05, 0.5, 5 and
50 ng/mL. Chemerin 0.05 ng/mL did not signiﬁcantly affect contrac-
tile responses induced by PE and ET-1. Chemerin 50 ng/mL produced
effects similar to those observed with 5 ng/mL. Previous studies have
estimated that the plasma and serum concentrations of active
chemerin are 3.0 and 4.4 nM, respectively, in humans and 0.6 and
0.5 nM, respectively, in mice (Zabel et al., 2006). Therefore, the
concentration used in the present study corresponds to physiological
levels of chemerin.Vascular function studies
Cumulative concentration–response curves to PE (0.001–10 μM)
and ET-1 (0.001–30 nM) were performed in aortic rings previously
incubated with chemerin (0.5 ng/mL or 5 ng/mL, for 1 or 24 h) or
vehicle. To determine whether chemerin effects were dependent on
the endothelium, responses were also assessed in endothelium-
denuded arteries.
To determine the involvement of MEK-ERK1/2 pathway on
chemerin effects, concentration-effect curves to PE and ET-1 were
performed either in the absence (control) or in the presence of the
MEK1/2 inhibitor PD98059 (1 μM). The protocol was performed in
both endothelium-intact and endothelium-denuded vessels incubat-
ed with chemerin for 1 or 24 h. Experiments were also performed
with 10 μM PD98059 (data not shown), and similar results were
observed when compared with those observed with 1 μM PD98059.
The effects of another MEK/ERK inhibitor, the compound U0126,
were also investigated and similar results were obtained when com-
pared with PD98059 (data not shown).
In order to investigate if the increased contractile response to PE
after incubation with chemerin was associated with an overall impair-
ment of the ET-1 system, rather than a speciﬁc PE-mediated signaling
pathway, concentration–response curves to PE were performed in
arteries incubated with a selective ETA receptor antagonist (BQ-123,
0.1 μM). Tissues were incubated with the inhibitors for 30 min prior to
the incubation with chemerin. Each preparation was tested with a
single agent.Western blotting
To test whether chemerin alters the activity of MEK1/2, ERK1/2,
and MKP1, endothelium-intact vessels were incubated with 0.5 ng/mL
chemerin or vehicle for 1 or 24 h, and the activation of these proteins
was examined. After the incubation protocols were performed, vessels
were frozen in liquid nitrogen and proteins were extracted (50 μg)
and separated by electrophoresis on 8% polyacrylamide gels and trans-
ferred to nitrocellulose membranes. Nonspeciﬁc binding sites were
blocked with 5% skim milk in Tris-buffered saline solution with Tween
(0.1%) for 1 h at 24 °C. Membranes were incubated with antibodies (at
the indicated dilutions) overnight at 4 °C. Antibodies were as follows:
anti-MEK1/2 (1:250, Sigma), anti-phospho MEK1/2 (1:1000, Sigma),
anti-ERK1/2 (1:1000, Cell Signaling), anti-phospho ERK1/2 (1:1000,
Cell Signaling), anti MKP1 (1:1000, Sigma), and anti-β-actin (1:20000,
Sigma). After incubation with secondary antibodies, signals were
revealed by chemiluminescence, visualized by autoradiography and
quantiﬁed densitometrically. Results were normalized to β-actin ex-
pression and expressed as units relative to the control.Drugs
Phenylephrine, acetylcholine, PD98059, BQ-123, and endothelin-1
were purchased from Sigma Chemical Co (St. Louis, MO). Chemerin
was purchased from R&D Systems, Inc (Minneapolis, MN).
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Contraction to PE andET-1 is expressed as percentage of KCl-induced
response. The individual concentration–response curveswere ﬁtted into
a curve by non-linear regression analysis. pD2 (deﬁned as the negative
logarithm of the EC50 values) and maximal response (Emax) were
compared by t-tests or ANOVA, when appropriated. The Prism software,
version 5.0 (GraphPad Software Inc., San. Diego, CA, USA) was used to
analyze these parameters as well as to ﬁt the sigmoidal curves. Data
are presented as mean±SEM. N represents the number of animals
used. p Values less than 0.05 were considered signiﬁcant.Results
Chemerin potentiates PE-induced vasoconstriction
The sensitivity to PE was signiﬁcantly increased in vessels treated
with 0.5 ng/mL chemerin for 1 h (pD2=7.8±0.1) when compared to
vessels treated with either vehicle (pD2=6.8±0.05), or 5 ng/mL
chemerin (pD2=6.6±0.05) (n=5, Fig. 1A). However, incubation with
chemerin for 24 h decreased the maximal vascular contractile response
to PE (Emax in %, vehicle=144.6±2.6; chemerin 0.5 ng/mL=100.4±
2.5; chemerin 5 ng/mL=82.4±3.6, n=5, pb0.05; Fig. 1B).
A negative modulatory role of the endothelium on chemerin effects
was observed in vessels incubated with the adipokine for both 1 and
24 h. Incubationwith chemerin for 1 h signiﬁcantly potentiated themax-
imal vascular contractile responses to PE in endothelium-denuded
vessels (Emax in %, vehicle=105.3±1.6; chemerin 0.5 ng/mL=141.2±
1.9; chemerin 5 ng/mL=141.0.4±10.1, n=5, pb0.05; Fig. 1C). A similar
effect was observed in vessels incubated with chemerin for 24 h (EmaxFig. 1. Chemerin potentiates PE-induced vasoconstriction. The sensitivity to phenylephrine
Chemerin incubation for 24 h decreased the maximal vascular contractile response to PE (B)
responses to PE after incubation with chemerin for 1 h (C). Similar effects were observed in
calculated relatively to the contractile response produced by 120 mmol/L KCl, which was tak
*, pb0.05 vs. control (vehicle).in %, vehicle=104.0±3.1; chemerin 0.5 ng/mL=133.±2.3; chemerin
5 ng/mL=150.0.4±7.5, n=5, pb0.05; Fig. 1D).
Chemerin potentiates ET-1-induced vasoconstriction
Chemerin incubation for 1 h augmented the vascular sensitivity to
ET-1. Similar effects were observed in vessels incubated with both con-
centrations of chemerin (pD2, vehicle=9.2±0.06; chemerin 0.5 ng/
mL=10.5±0.1; chemerin 5 ng/mL=10.2±0.06, n=5, pb0.05;
Fig. 2A).
Chemerin incubation for 24 h signiﬁcantly increased the sensitivity
to ET-1 in vessels treated with 0.5 ng/mL chemerin (pD2=7.8±0.1),
when compared to vessels treated with either vehicle (pD2=6.8±
0.05) or 5 ng/mL chemerin (pD2=6.6±0.05) (n=5, Fig. 2B).
In vessels without endothelium, both concentrations of chemerin
(1 h-incubation) augmented the vasoconstrictor sensitivity to ET-1
(pD2, vehicle=9.6±0.1; chemerin 0.5 ng/mL=11.6±0.03; chemerin
5 ng/mL=11.3±0.06, n=5, pb0.05; Fig. 2C). In vessels incubated
with chemerin for 24 h, the potentiating effect on ET-1-induced
contraction was observed only with the higher concentration (Emax in %,
vehicle=102.2±6.6; chemerin 0.5 ng/mL=119.3±4.7; chemerin
5 ng/mL=170.5±9.2, n=5, pb0.05; Fig. 2D).
The vascular effects of chemerin are dependent on ERK1/2 activation
Incubation of vessels with the ERK1/2 inhibitor, the compound
PD98059, 30 min before the incubation with chemerin (for 1 h), abol-
ished the effects of this cytokine on PE-induced vasoconstriction
(pD2; vehicle=6.7±0.1; chemerin 0.5 ng/mL=7.7±0.1; chemerin
5 ng/mL=6.6±0.04; vehicle+PD98059=7.2±0.05; chemerin 0.5 ng/(PE) was increased in thoracic aortic rings treated for 1 h with 0.5 ng mL chemerin (A).
. Removal of the endothelium signiﬁcantly potentiated the maximal vascular contractile
vessels incubated with chemerin for 24 h (D). Experimental values of contraction were
en as 100%. Results are presented as mean±SEM for n=5 in each experimental group.
Fig. 2. Chemerin potentiates ET-1-induced vasoconstriction. Chemerin incubation for 1 h (A) and 24 h (B) augmented the sensitivity to endothelin-1 (ET-1). A negative modulatory
effect of the endothelium was observed on the effects of chemerin on ET-1 responses. In vessels without endothelium, chemerin incubation for 1 h (C) and 24 h (D) further aug-
mented the vasoconstrictor sensitivity to ET-1. Experimental values of contraction were calculated relatively to the contractile response produced by 120 mmol/L KCl, which was
taken as 100%. Results are presented as mean±SEM for n=5 in each experimental group. *, pb0.05 vs. control (vehicle).
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(n=6, Fig. 3A). The same effect was observed in endothelium-denuded
vessels (Emax in %, vehicle=105.2±1.6; chemerin 0.5 ng/mL=143.0±
2.1; chemerin 5 ng/mL=140.0±6.8; vehicle+PD98059=102.3±1.4;Fig. 3. The vascular effects of chemerin are dependent on ERK1/2 activation. The ERK1/2
abolished chemerin effects on phenylephrine (PE)-induced contraction (A). The same effec
the 24 h-effects of chemerin on ET-1-induced vasoconstriction (C). PD98059 did not chan
of contraction were calculated relatively to the contractile response produced by 120 mm
each experimental group. *, pb0.05 vs. Control (vehicle); #, pb0.05 vs. respective group inchemerin 0.5 ng/mL+PD98059=119.3±1.3; chemerin 5 ng/mL+
PD98059=106.4±4.2, n=6, pb0.05; Fig. 3B).
The ERK1/2 inhibitor also abolished the 24-hour effects of che-
merin on ET-1-induced constriction in endothelium-intact arteriesinhibitor (PD98059), added 30 min before the incubation with chemerin (for 1 h),
t was observed in endothelium-denuded vessels (B). ERK1/2 inhibition also abolished
ge the effects of chemerin in endothelium-denuded vessels (D). Experimental values
ol/L KCl, which was taken as 100%. Results are presented as mean±SEM for n=6 in
the absence of PD98059.
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5 ng/mL=10.8±0.1; vehicle+PD98059=9.2±0.05; chemerin 0.5 ng/
mL+PD98059=9.3±0.1; chemerin 5 ng/mL+PD98059=9.4±0.06,
pb0.05; n=6, Fig. 3C). However, PD98059 attenuated but did not block
chemerin effects in endothelium-denuded vessels (Fig. 3D).
ETA receptor activation mediates vascular effects of chemerin on PE
responses
Chemerin effects on PE-induced vasoconstriction were abolished by
the ETA antagonist BQ-123, (pD2; vehicle=6.7±0.1; chemerin 0.5 ng/
mL=7.7±0.1; chemerin 5 ng/mL=6.6±0.04; vehicle+BQ123=
6.8±0.05; chemerin 0.5 ng/mL+BQ123=7.0±0.04; chemerin 5 ng/
mL+BQ123=6.7±0.05; n=6, Fig. 4A). Similar results were observed
in endothelium-denuded vessels incubated with the ETA antagonist
(Emax in %, vehicle=103.0±1.6; chemerin 0.5 ng/mL=138.0±
1.9; chemerin 5 ng/mL=140.2±5.9; vehicle+BQ-123=105.6±3.0;
chemerin 0.5 ng/mL+BQ-123=90.07±2.5; chemerin 5 ng/mL+
BQ-123=94.7±1.8, n=6, pb0.05; Fig. 4B).
Chemerin induces MEK-ERK1/2 pathway activation
Chemerin (0.5 ng/mL and 5 ng/mL for 1 h) increased vascular
protein expression of phosphorylated MEK1/2 (Fig. 5A) and ERK1/2
(Fig. 5B), vs. vehicle (PBS)-treated aortic rings. ET-1 also increased
vascular protein expression of phosphorylated MEK1/2 and ERK1/2
(values were similar to those observed in aortic rings treated with
chemerin). MEK1/2 and ERK1/2 phosphorylation was further increased
in vessels incubatedwith a combination of ET-1 and chemerin. Chemerin
incubation for 1 h also increased vascular protein expression of theMAPK
phosphatase 1 (MKP1), an enzyme that inactivates MAPK signaling
(n=4, Fig. 5C).
Chemerin incubation for 24 h did not change the vascular protein
expression of phosphorylated MEK1/2 (Fig. 5D) or ERK1/2 (Fig. 5E),
vs. vehicle (PBS)-treated aortic rings. However, ET-1 increased vascular
protein expression of phosphorylated MEK1/2 and ERK1/2. Similarly
to the observed in vessels incubated for 1 h, MEK1/2 and ERK1/2
phosphorylation was further increased in vessels incubated with a
combination of ET-1 and chemerin. The protein expression of the MKP1
was also increased after chemerin incubation for 24 h (n=4, Fig. 5F).
Discussion
The present study shows for the ﬁrst time that the adipokine
chemerin augments vascular responses to contractile stimuli and that
ET-1-activated pathways contribute to the vascular changes produced
by this cytokine. We also demonstrated that the vascular effects of
chemerin occur through activation of MEK-ERK1/2 pathway.
Considering that cytokines activate several signaling pathways
and mediators of vascular contraction (Klemm et al., 1995; Vicaut etFig. 4. ETA receptor activation mediates vascular effects of chemerin on PE responses. Chem
antagonist, the compound BQ-123 both in endothelium-intact (A) and endothelium-denu
contractile response produced by 120 mmol/L KCl, which was taken as 100%. Results are
(vehicle); #, pb0.05 vs. respective group in the absence of BQ123.al., 1996; Pickkers et al., 2002; Vila and Mercedes, 2005), and given
that ET-1 plays a major role on vascular dysfunction in conditions
characterized by increased circulating levels of adipokines (Schiffrin,
2005; Carneiro et al., 2008; Weil et al., 2011), we hypothesized that
chemerin increases vascular responses to contractile stimuli via activa-
tion of ETA receptors and MEK-ERK1/2-mediated pathways. In fact,
short term exposure (1 h) to chemerin augmented vasoconstriction in-
duced by both the α1-adrenergic agonist PE and ET-1 in endothelium-
intact vessels. The potentiating effect of chemerin on ET-1 responses
was also observed after incubation for 24 h. Of relevance, chronic
chemerin incubation did not produce consistent potentiation of vaso-
constriction, which indicates that chemerin can activate additional
pathways in a time-dependent manner. In addition, the endothelium
seems to negatively modulate chemerin effects. This is supported by
our ﬁndings that chemerin effects on PE and ET-1 contractions were
greater in endothelium-denuded aortic rings.
Unlike the effects produced on ET-1 responses, chemerin incubation
for 24 h (at the two concentrations) decreased the maximal vascular
contractile response to PE. Considering that contractile responses are
modulated by endothelium-derived factors and that the signaling path-
ways activated by PE differ from those activated by ET-1, it might be
suggested that compensatorymechanisms are activated in these vessels
to counteract chemerin effects on PE responses after prolonged periods
of incubation. This hypothesis is further supported by the observation
that in endothelium-denuded vessels, chemerin (at the two different
concentrations, after 24 h of incubation) signiﬁcantly potentiated the
maximal vascular contractile response to PE. These data provide addi-
tional evidence that the endothelium negatively modulates the effects
of the adipokine chemerin on PE effects in the vascular smooth muscle
cells. In addition, our results also allow us to suggest that chemerin
plays a major role inﬂuencing ET-1 responses, since its effects (even at
low concentrations) in the contractile response induced by this agonist
was not negatively modulated by the endothelium after 24 h incuba-
tion. To clarify whether chemerin effects on vascular contraction were
dependent on the ET-1 pathway, concentration-effect curves to PE
were performed in the presence of an ETA antagonist. Treatment with
BQ-123 for 30 min previous to the incubation with chemerin abolished
the enhanced vascular contractile response to PE. This result indicates
that the ETA receptor subtype mediates the effects of chemerin and
also adds an important insight into the role of ET-1 systemon the effects
of adipokines on vascular function.
Increased activation of signaling pathways involved in vasoconstric-
tion may also contribute to the vascular effects of cytokines (Yamawaki,
2011). A key signaling pathway recruited by ET-1 receptor activation is
theMAPK cascade (Bouallegue et al., 2007). Several reports have demon-
strated that ET-1 activates MEK1/2, which in turn phosphorylates ERK1/
2, promoting contraction of the vascular smooth muscle cells (Zubkov
et al., 2000; Ishihata et al., 2002; Ansari et al., 2004). Although chemerin
signaling pathways have not been well established, chemerin receptor
(CMKLR1) activation is reported to increase the phosphorylation oferin effects on phenylephrine (PE)-induced vasoconstriction were abolished by the ETA
ded (B) vessels. Experimental values of contraction were calculated relatively to the
presented as mean±SEM for n=6 in each experimental group. *, pb0.05 vs. Control
Fig. 5. Chemerin induces MEK-ERK1/2 pathway activation. Chemerin (0.5 ng/mL, for 1 h) and ET-1 (0.1 μM, for 10 min) increased vascular protein expression of phosphorylatedMEK1/2
(A) and ERK1/2 (B). In addition, MEK1/2 and ERK1/2 phosphorylation was further increased in vessels incubated with a combination of ET-1 and chemerin. Chemerin incubation for 1 h
also increased vascular protein expression ofMKP1 (C). Chemerin incubation for 24 h did not change the vascular protein expression of phosphorylatedMEK1/2 (D) or ERK1/2 (E). How-
ever, ET-1 increased the protein expression of phosphorylatedMEK1/2 and ERK1/2.MEK1/2 and ERK1/2 phosphorylationwas further increased in vessels incubatedwith a combination of
ET-1 and chemerin. MKP1 protein expression was also increased after chemerin incubation for 24 h (F). Top, representativeWestern blotting images of (A)MEK1/2 proteins, (B) ERK1/2,
and (C) MKP1. Bottom, corresponding bar graphs showing the relative expression of MEK1/2, ERK1/2, andMKP1 after normalization to β-actin expression. Results are presented
as mean±SEM for n=4 in each experimental group. *, pb0.05 vs. control (vehicle); #, pb0.05 vs. Chemerin+ET-1. Endothelium-intact vessels were used in these experiments.
605N.S. Lobato et al. / Life Sciences 91 (2012) 600–606ERK1/2 (Wittamer et al., 2003). The relevance of this effect to the
vascular actions of chemerin has not been described. In our study, inhibi-
tion of MEK1/2 with the compound PD98059 abolished the effects
of chemerin on ET-1-induced vasoconstriction. Additionally, chemerin
effects on PE-induced vascular responses also rely on this pathway.
Similarly to those observed with ET-1, chemerin effects on PE-induced
vasoconstriction were abolished by MEK1/2 inhibition, both in vessels
with andwithout endothelium. Thisﬁnding strongly suggests that activa-
tion of the MEK-ERK1/2 pathway contributes to chemerin effects on
vascular reactivity.
To conﬁrm that chemerin activates MEK1/2-mediated down-
stream responses, we determined the phosphorylation of these pro-
teins. Western blotting analysis showed that chemerin (at 1 h)increased the phosphorylation of MEK1/2 and ERK1/2, a primary target
of activated MEK1/2. In addition, chemerin potentiated ET-1-induced
MEK1/2 and ERK1/2 phosphorylation. These data support our previous
results showing that chemerin potentiates vasoconstriction to ET-1 by
activating the MEK-ERK1/2 pathway. It is important to consider that
although our results indicate that chemerin and ET-1 act through a
common intracellular signaling transduction pathway, chemerin
seems to activate additional mechanisms to potentiate vascular ET-1
responses. Increased activity of other kinases may be involved in these
effects. Thus, potentiation of ET-1 signaling or even transactivation of
ET-1-activated pathways by chemerin may provide an explanation for
the potentiation of ET-1-induced MEK and ERK phosphorylation by
chemerin.
606 N.S. Lobato et al. / Life Sciences 91 (2012) 600–606We further probed themechanisms leading to vascular activation of
ERK1/2 by chemerin. MAPK pathway activation can be modulated at
various steps, including receptor desensitization, dissociation of signal-
ing complexes from receptor and deactivation of pathway mediators
(Liu et al., 2007). Accordingly, phosphatases are important regulators
of the MAPK pathway. MKPs are dual-speciﬁc phosphatases (DUSPs)
that dephosphorylate tyrosine and threonine residues in MAPKs and
thereby inactivate them (Boutros et al., 2008). MAPK phosphatase 1
(MKP1) is known to inactivate ERK1/2 (Boutros et al., 2008). Therefore,
it is possible that chemerin increases ERK1/2 activation and the
vasoconstrictor response to ET-1 by decreasing MKP1 activity. Howev-
er, we observed that chemerin increased MKP1 levels, suggesting
that chemerin regulates MKP1 expression as a negative feedback to
modulate its effects on ERK1/2 activation.
Conclusions
Our study demonstrates that the adipokine chemerin potentiates
the contractile response induced by ET-1 and PE, acting in both the
endothelium and the vascular smooth muscle. A negative modulatory
role of the endothelium on chemerin effects was also demonstrated.
In addition, our data show that ETA receptor activation mediates
chemerin effects on PE-induced response. Finally, we also showed
that activation of the MEK-ERK1/2 pathway is involved on chemerin
effects on ET-1 and PE-induced responses. These ﬁndings will contrib-
ute to a better understanding of how this cytokine can affect vascular
reactivity in physiological and pathophysiological conditions.
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